A number of other analysts also recently issued reports on the stock. Jefferies Group raised their price target on shares of Neurocrine Biosciences to $105.00 and gave the company a buy rating in a report on Friday, January 5th. Leerink Swann raised their price target on shares of Neurocrine Biosciences from $90.00 to $96.00 and gave the company an outperform rating in a report on Tuesday, February 20th. Barclays reaffirmed an overweight rating and set a $100.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, February 14th. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the company an overweight rating in a report on Wednesday, February 14th. Finally, BidaskClub raised shares of Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Wednesday, January 31st. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $95.23.
Shares of Neurocrine Biosciences (NBIX) opened at $90.36 on Tuesday. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $92.98. The company has a market cap of $8,087.29, a PE ratio of -55.10 and a beta of 0.31. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20.
In other news, CEO Kevin Charles Gorman sold 3,750 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $78.89, for a total value of $295,837.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Haig P. Bozigian sold 1,625 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total transaction of $128,570.00. The disclosure for this sale can be found here. Insiders sold a total of 399,589 shares of company stock worth $32,443,795 in the last quarter. Company insiders own 4.80% of the company’s stock.
Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Amalgamated Bank raised its stake in Neurocrine Biosciences by 5.7% during the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock worth $1,357,000 after acquiring an additional 947 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Neurocrine Biosciences by 25.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after acquiring an additional 1,200 shares during the period. Swiss National Bank raised its stake in Neurocrine Biosciences by 1.3% during the 3rd quarter. Swiss National Bank now owns 147,300 shares of the company’s stock worth $9,027,000 after acquiring an additional 1,900 shares during the period. Finally, Crow Point Partners LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth approximately $145,000.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3261713/neurocrine-biosciences-nbix-given-a-110-00-price-target-by-oppenheimer-analysts.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.